RTKN

Across TCGA pan-cancer cohorts, RTKN mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated RTKN data layer compared with 22 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher RTKN mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated RTKN expression acts as an unfavorable survival marker, although some lineages such as UCEC and LSCC show a favorable association.

GBM, LUAD, and CCRCC are the cancer types where RTKN mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Tertile	All	0.607	0.873	.001	26	view →
LUAD	OS	Median	II,III,IV	0.306	0.853	.001	22	view →
CCRCC	DFS	Median	All	0.717	0.896	.007	7	view →
UCEC	OS	Median	All	0.983	0.852	.012	6	view →
LSCC	DFS	Median	All	0.953	0.923	.027	5	view →
PDAC	DFS	Median	IV	0.250	0.934	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RTKN–GBM (DFS)

Open the GBM breakdown →